ImmunityBio Surges 11% as ANKTIVA Sales Drive 94% Revenue Growth

NEW YORK, September 30 —

ImmunityBio, Inc. (IBRX) surged 11% after Q4 results showed ANKTIVA-powered revenue up 94% YoY, catching a 31.3% short float badly positioned.

ANKTIVA's Commercial Debut: Revenue Nearly Doubled, But So Did the Cash Gap

ANKTIVA's launch delivered the ramp bulls needed: TTM sales hit $166mn, a 94% YoY jump that repositions ImmunityBio from a clinical-stage story into a commercial one. For a company whose pipeline had been almost entirely pre-revenue, that inflection is real. The complication is that ImmunityBio burned through $187mn in free cash flow over the same period, spending more than it earned in total sales.

The Q4 print proves ANKTIVA sells. It does not yet prove it scales profitably.

31% of the Float Was Short, and It Still Is

With 31.3% of the float sold short, Wednesday's 11% gain was not purely an earnings trade. Shorts covering into a positive print create mechanical buying pressure, which means the stock's reaction likely overstates any genuine shift in fundamental sentiment. The float remains heavily positioned against the company heading into Q1 2026 results. That setup cuts both ways: another strong ANKTIVA quarter forces more covering, while soft guidance produces rapid unwinding in a thin book.

Investors arriving after the headline pop are buying into an already-crowded momentum trade at $9.44.

The Burn Rate Is the Risk the Revenue Chart Obscures

That revenue figure looks compelling until placed against the $187mn FCF deficit. ImmunityBio is burning more cash than it generates in total sales, a structural imbalance that demands either a sharp acceleration in ANKTIVA volumes or additional equity capital. Trailing EPS of -$0.95 per share and a -74.5x forward P/E together imply the market is pricing a multi-year path to breakeven. Soon-Shiong's oncology network expansion adds operating leverage over time, but that lever only matters if the cash runway holds long enough to reach it.

Full-Year 2026 Guidance Is the Number That Settles the Argument

The 2026 full-year ANKTIVA net product revenue target is the only figure that will clarify whether Q4's momentum reflects a durable ramp or a favorable single-quarter comp. A guidance range above consensus would validate the bull case and intensify pressure on the remaining short float. A range implying deceleration would expose that growth rate as a high-water mark. Watch the Q4 earnings call transcript for that figure. At $9.44 per share and a -74.5x forward P/E, the stock's valuation only makes sense if ANKTIVA volumes scale materially through 2026, that is the specific number that would prove the thesis wrong if it disappoints.

For a full breakdown of ImmunityBio's fundamentals, cash position, and valuation multiples, generate a Basis Report on IBRX. To stress-test the cash flow trajectory against a range of ANKTIVA growth assumptions, use the DCF calculator.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.